Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Interrogating metabolic crosstalk in the tumour-bone microenvironment, new research from the Edwards group shows how the pentose phosphate pathway contributes to prostate cancer bone metastasis.

Prostate cancer cell division © SHUTTERSTOCK

Prostate cancer is the second leading cause of cancer-related death in men. While overall five-year survival rates for prostate cancer are 97.8%, in metastatic disease this falls to only 30%.

Once prostate cancer spreads to bone, treatment options are limited and the malignancy becomes incurable. Prostate cancer cells are exquisitely dependent upon cellular interactions within the bone microenvironment to drive both tumour growth and survival and the development of the associated bone disease. Research from Prof. Claire Edwards' team at the Botnar Research Centre, and published in Science Advances, identifies a new mechanism by which the bone microenvironment alters the energy requirements of prostate cancer cells to support disease progression.

"The importance of cellular crosstalk within the tumour-bone microenvironment has long been recognised," said Claire Edwards. "In this study we show how bone cells alter the metabolic activity of prostate cancer cells."

The first author of the study, Dr. Jessica Whitburn, said: "Through a collaboration with Prof. Tomoyoshi Soga, Keio University, we used metabolomic profiling to identify changes in the pentose phosphate pathway. Genetic and pharmacologic manipulation of G6PD, the rate-limiting enzyme of this pathway, had a significant impact on prostate cancer cell growth, migration, metabolism and chemosensitivity.

"The ability of cancer cells to reprogramme their cellular metabolism has recently been recognised as an additional hallmark of cancer. By understanding how the bone microenvironment drives the metabolic plasticity of prostate cancer cells, we reveal new mechanisms underlying disease pathogenesis and new metabolic targets for the treatment of prostate cancer bone metastasis."

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.